# Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

> **NCT03315039** · PHASE1,PHASE2 · COMPLETED · sponsor: **Moleculin Biotech, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Liposomal Annamycin

## Key facts

- **NCT ID:** NCT03315039
- **Lead sponsor:** Moleculin Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2020-01-14
- **Final completion:** 2020-06-20
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315039, "Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03315039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*